Index

Note: page numbers in italics refer to figures; those in bold to tables or boxes.

abacavir 568
acamprosate 369, 370
acetylcholinesterase (AChE) inhibitors
adverse effects 497–8
Alzheimer’s disease 490, 491–2
behavioural and psychological symptoms 511–12
combination therapy 502, 503
delirium 551–2
dementia with Lewy bodies 505
dosing 491, 496
drug interactions 171, 498–9, 500
efficacy in dementia 490–4, 495
Huntington’s disease 556
mechanism of action 490–4, 495
NICE guidance 499
Parkinson’s disease 520, 520–1
switching 496
tolerability 497
vascular dementia 504–5
see also donepezil; galantamine; rivastigmine
N-acetylcysteine, refractory schizophrenia 71
activated partial thromboplastin time 600
acutely disturbed behaviour 531–8
Clopixol Acuphase 537
intoxication with street drugs 414
rapid tranquillisation 531–2, 533–6
recommended interventions 533
acute mania see mania, acute
S-adenosyl-l-methionine 230
ADHD see attention deficit hyperactivity disorder
adherence (to medication) 628–33
assessment 631–2
factors affecting 629
rates 629–30
schizophrenia 25, 42, 62, 629–30
strategies for improving 630–1, 632–3
adolescents see children and adolescents
affective disorders
anticonvulsant withdrawal 429–30
caffeine consumption 622
see also bipolar disorder; depression; mania
Afro-Caribbeans, clozapine-induced neutropenia 84
aging see elderly
aggressive behaviour
adults with learning disabilities 542–3
autism spectrum disorders 339–40
carbamazepine 169
dementia see behavioural and psychological symptoms (BPSD) of dementia
drug-induced 304–6
lithium 161
pathological, children and adolescents 340–1
valproate 155
see also acutely disturbed behaviour
agitation
dementia see behavioural and psychological symptoms (BPSD) of dementia
non-psychotropics causing 580
agomelatine 213
cardiac effects 259
discontinuation symptoms 275
elderly 245
hepatic impairment 483
minimum effective dose 218
overdose 589
relative adverse effects 249
renal impairment 468
sexual adverse effects 265, 266
swapping/switching 271–2, 273
agranulocytosis clozapine-induced 77, 79, 81, 84–8
psychotropics causing 601
see also neutropenia
AIDS see HIV infection/AIDS
akathisia, antipsychotic-induced 99–101
treatment 103–5, 104
D-alanine, refractory schizophrenia 70
alanine transference 594
albumin, plasma 594
alcohol
buprenorphine and 386
driving and 635
drug interactions 608–11, 610–11
metabolism 608, 609, 610
methadone interaction 379
during pregnancy 371–2
Index

alcohol dehydrogenase (ADH) 608, 609
drugs inhibiting 610
alcohol dependence/misuse 356–72
driving regulations 640–1
drug interactions 609, 610, 611–12
mild, assisted withdrawal 361, 366
moderate, assisted withdrawal 361, 366
pregnancy 371–2
psychotropic drug choice 612
relapse prevention 369–71
severe, assisted withdrawal 361–2, 364–6, 366

treatment see alcohol withdrawal
alcohol withdrawal 356, 356–69, 366
assessment 358, 359–60
benzodiazepines 360–7
combined fixed-dose and symptom-triggered regimen 363–4, 364
community-based 358
fixed-dose regimen 361–2, 362
front-loading regimen 362, 362–3
hallucinations 369
inpatient protocol 364–6
management 357–8
medically compromised patients 366, 366–7
pregnancy 371–2
seizure prophylaxis 169, 369
symptomatic therapy 370
symptom-triggered regimen 362, 362
syndrome 356–7
vitamin supplementation 367–9
aldehyde dehydrogenase 608, 609
drugs inhibiting 610
alkaline phosphatase 595
allopurinol 70, 179
alpha-2 adrenergic agonists 339, 346
alprostadil 145, 146
Alzheimer’s disease 490–504
antidepressants 512–13
behavioural and psychological symptoms (BPSD) 509–18
combination treatment 502
efficacy of drug treatment 490–4
mechanism of drug action 490
NICE guidance 499, 499
other treatments 502–4
quantifying drug effects 494–6
switching between drugs 496
see also acetylcholinesterase inhibitors; antidementia drugs; memantine
amantadine
antipsychotic-induced weight gain 129
catatonia 113
Huntington’s disease 555
hyperprolactinaemia 125
multiple sclerosis 525
resistant depression 229
sexual dysfunction 145, 146
tardive dyskinesia 107
amifutamone see bupropion
amfetamine depression 239
drug interactions 415–16
misuse 406–7, 411
resistant depression 230
see also dexamfetamine
amino acids, tardive dyskinesia 107
6-(2-aminopropyl)benzofuran (6-APB) 415–16
amisulpride adverse effects 151
breast feeding 453
clozapine augmentation 67
clozapine-related hypersalivation 90
cost 20
delirium 549
dementia 510
diabetes and 134
epilepsy 421
hepatic impairment 479, 480
Huntington’s disease 556
maximum licensed dose 17
minimum effective dose 15
negative symptoms 57
overdose 589
plasma level monitoring 3, 4
psychotic depression 233
refractory schizophrenia 70, 71, 72
relative efficacy 12
sexual adverse effects 144
amitriptyline 207
adverse effects 249
child and adolescent depression 318–19
395
clozapine-related hypersalivation 90
epilepsy 421
gel 288, 290
intramuscular 288, 289
intravenous 287, 289
plasma level monitoring 4
pregnancy 436, 438
rectal 289, 290
renal impairment 468
surgical patients 560
amnesia, alcohol-induced 611
amoaxpine, epilepsy 421
amphetamine see amfetamine
amylose, serum 595
anaesthesia, psychotropics and 558–64, 559–62
analgesia, opioid-dependent patients 380–1, 386–7, 392
angiotensin II antagonists, lithium interactions 164, 165
angiotensin converting enzyme (ACE) inhibitors, lithium interactions 164, 165
anorexia nervosa 527–8, 529
Antabuse see disulfiram
‘Antabuse reaction’ 609, 610
anticholinergic drugs
extrapyramidal side-effects 101
with long-acting injection
antipsychotics 42
street drug interactions 416
anticholinergic side-effects
antidepressants 249
antipsychotics 143, 151
renal impairment and 463
anticholinesterases see acetylcholinesterase (AChE) inhibitors
anticonvulsants
adults with learning disabilities 542
alcohol withdrawal 369
autism spectrum disorders 338
clozapine-induced seizures 77
dementia 513
depression/psychosis and 420–3
driving and 635
drug interactions 422–3, 424, 425–8
ECT seizure threshold and 237
plasma level monitoring 1–10
pregnancy 441, 441, 442
surgery and 559
withdrawing 428–30, 429
women of childbearing age 156–7
see also mood stabilisers; specific agents
antidementia drugs 490–503, 491–2
adverse effects 491, 497–8
behavioural and psychological symptoms 511–12
combinations 502
dosing 491, 496
drug interactions 498–9, 500–1
efficacy 490–4, 495
Huntington’s disease 556
mechanisms of action 490
NICE guidance 499, 499
Parkinson’s disease 520–1
quantifying effects 494–6
renal impairment 464, 474–5
switching between 496
tolerance 497
see also acetylcholinesterase (AChE) inhibitors; memantine
antidepressants 201–91, 203–15
adverse effects 249–52
comparison table 249
elderly 244–5
relative 202, 203–15
alcohol misusers 612
alternative routes of administration
anxiety spectrum disorders 217, 292–7, 293–5
children and adolescents 328–9
benzodiazepine withdrawal 309
biochemical side-effects 594–9
bipolar depression 185, 186, 187
bipolar disorder 194, 195
borderline personality disorder 546
breast feeding 447, 448–52
cardiac effects 257–64, 258–9
children and adolescents 317–19, 328–9
costs 203–15
cross-tapering 270–3
dementia 512–13
depression 201–91
algorithm 198
children and adolescents 317–19
choice of agent 202, 203–15
duration of treatment 216
effectiveness 201–2
minimum effective doses 218
next-step treatments 217
official guidance 200
onset of action 202
prescribing principles 199
prophylaxis 219–22, 220
diabetes and 256
discontinuation symptoms 270–7, 275, 276
driving and 635
drug interactions 171, 216, 281–2, 281–6, 283–5, 422–3
eating disorders 528, 529
ECT seizure threshold and 235–6
elderly 243–6, 244–5
epilepsy and 419–20, 421
hepatic impairment 479, 482–3
HIV infection 565
Huntington’s disease 556
hyperprolactinaemia and 268–9, 268–70
hyponatraemic effects 250, 250–2
indications 203–15
intramuscular 288, 289
intravenous 286–90, 287–8
lithium augmentation 160–1
multiple sclerosis 523
overdose 588–9
Parkinson’s disease 519
patient information 221, 276
post-stroke depression 247, 247
pregnancy 436–7, 438, 442
psychotic depression 233
rectal 289, 290
renal impairment 464, 468–71
resistant depression 222–32, 223, 232
schizophrenia negative symptoms 58
sexual dysfunction and 264–8, 265
street drug interactions 416
sublingual 286, 287
suicidality and 216
surgical patients 599–60
swapping/stopping 270–7, 271–2
transdermal 288, 290
see also specific agents
antidiuretic hormone, syndrome of inappropriate secretion (SIADH) 148, 149, 250
antiepileptics see anticonvulsants
antimuscarinic drugs
akathisia 104
see also anticholinergic drugs
antipsychotics 11–152
acme mania/hypomania 176, 177, 178
adherence 25, 42, 62
adults with learning disabilities 541
adverse effects 12, 98–151
combination therapy 51
dose-related 56
first- vs second-generation agents 39–40
relative 151
see also specific adverse effects
alcohol misusers 612
anorexia nervosa 528
atypical see second-generation antipsychotics
biochemical side-effects 594–9
bipolar disorder 174–5, 182–4, 194
borderline personality disorder 545–6
breast feeding 447, 453–5
cardiovascular effects 115–23
catatonia 114
children and adolescents attention deficit hyperactivity disorder 332
autism spectrum disorders 339–40
bipolar disorder 322, 323, 324
pathological aggression 340–1
psychosis 326, 326–7
tics and Tourette’s syndrome 346
combination therapy 21, 35, 51–4, 53
costs 20, 20
delirium 549–51
dementia 509–11
depot see long-acting injection (LAI) antipsychotics
diabetes association 132–8, 135, 151
dose-response observations 33–4
doses equivalent 13–14, 14
loading 23
maximum licensed 16–17
minimum effective 14–16, 15
when to increase 33
driving and 635
drug interactions 171, 422–3
ECT seizure threshold and 237
epilepsy and 419–20, 421–2
first-episode schizophrenia 24, 60
first generation see first-generation antipsychotics
hepatic impairment 479, 480–1
high-dose 54–7, 55, 56
HIV infection 564
Huntington’s disease 554–6
inadequate response 33–6, 36
long-acting injections see long-acting injection (LAI) antipsychotics
monitoring metabolic effects 26–30, 27–9
multiple sclerosis 524
negative symptoms 57, 57–60, 58
new 17–20
costs 20, 20
NICE guidelines 22, 22–3
overdose 589–90
Parkinson’s disease 520
plasma level variations 34
pregnancy 433–4, 435, 442–3
prescribing principles 21
prophylaxis 60–4, 61, 63
psychotic depression 233
rapid tranquillisation 531, 532, 533
relapse or acute exacerbation 25
relative efficacy 11–13
renal impairment 464, 465–7
resistant depression 224–5
second generation see second-generation antipsychotics
speed and onset of action 36–9, 39
street drug interactions 415
surgical patients 561
switching 31, 31–2, 34
therapeutic index 39
typical see first-generation antipsychotics
withdrawal 62
see also specific agents
Index

antiretroviral drugs 571
adverse psychiatric effects 571
drug interactions 414, 566–70
antisocial personality disorder, attention deficit hyperactivity disorder and 334
anxiety 292
children and adolescents 327–8
multiple sclerosis 523–4
nicotine use 615
non-psychotropics causing 580
anxiety spectrum disorders 292–301
antidepressants 217
benzodiazepines 292, 293–5, 301–2
caffeine consumption 622
children and adolescents 327–32
driving regulations 637
HIV infection 565
NICE guidance 297–8
pregabalin 297
pregnancy 441–2
psychological approaches 297
SSRIs/SNRIs 292–7, 301
biochemical side-effects 594–9
driving and 635
renal impairment 464, 473–4
see also benzodiazepines
6-APB (6-(2-aminopropyl)benzofuran) 415–16
aquaretics 148
aripiprazole
acute mania/hypomania 178
adults with learning disabilities 541
adverse effects 122, 151
augmentation 31, 32
autism spectrum disorders 339–40
bipolar depression 187
bipolar disorder 183, 192, 194
children and adolescents 323, 324
blood lipids and 139, 140
breast feeding 454
children and adolescents 326, 326
clozapine augmentation 67
cost 20, 180
delirium 550
dementia 510
diabetes and 134
dose-response observations 33
epilepsy 422
hepatic impairment 480
Huntington’s disease 555, 556
hyperprolaetinaemia 124–5
maximum licensed dose 17
minimum effective dose 15
overdose 589
plasma level monitoring 3, 5
psychotic depression 233
rapid tranquillisation 531, 533
children and adolescents 352
refractory schizophrenia 70, 71
relative efficacy 12
renal impairment 465
resistant depression 225
sexual function and 143, 144
switching to 128
tardive dyskinesia and 106
armodafinil, depression 239, 240
amphotera 624, 627
asenapine 17
acute mania/hypomania 178, 183
adverse effects 151
cost 180
maximum licensed dose 17
minimum effective dose 15
aspartate aminotransferase 595
Asperger’s syndrome 337
asthenia, non-psychotropics causing 581
ataxia, alcohol-induced 611
atenolol 76
atomoxetine
attention deficit hyperactivity disorder 332, 336
autism spectrum disorders 339
hepatic impairment 483
atropine 90
attention deficit hyperactivity disorder (ADHD) 332–7
adult 333–4
autism spectrum disorders 339
bipolar disorder and 324
driving regulations 639
NICE guidance 333
prescribing 335–6
attitudes to medication, assessing 631
atypical antipsychotics see second-generation antipsychotics
autism 337
autism spectrum disorders (ASD) 337–44
co-morbid problem behaviours 339–42
core symptoms 338–9
driving regulations 639
fluoxetine prescribing 342, 343
learning disability with 539, 541–2
risperidone prescribing 341–2
baclofen 346–7, 409
BALANCE study 154, 194–5
barbiturates
ECT seizure threshold and 237
misuse 411
basophil 600
behavioural and psychological symptoms (BPSD) of dementia 509–18
behavioural disorders
acute see acutely disturbed behaviour
driving regulations 640
learning disabilities 540, 541–3
non-psychotropics causing 581
behavioural therapies
dementia 513–14
drug-induced weight gain 128
opioid dependence 389–90
tics 345
benperidol, adverse effects 151
benzhexol 90
benzodiazepines 301–9
acute mania/hypomania 178
alcohol withdrawal 360–7
antagonism see flumazenil
antipsychotic-induced akathisia 104
anxiety disorders 292, 293–5, 301–2
anxiolytic 301–2
breast feeding 458
caffeine interaction 621
catatonia 113
children and adolescents 328
delirium 551
dementia 512
dependence 306–9
depression 302
detoxification 306–9, 308
disinhibitory reactions 304–6, 328
dosage reduction 307–8, 308
driving and 635
drug interactions 171, 303
ECT seizure threshold and 235
HIV infection 565
hypnotic 302, 312, 312
misuse 407–8, 411
multiple sclerosis 524
overdose 590
pregnancy 408, 441–2, 442
psychosis 302–3
rapid tranquillisation 302, 532, 533
renal impairment 473–4
side-effects 303
smoking and 616
street drug interactions 416
surgery and 561
tardive dyskinesia 106
tolerance test 307
withdrawal symptoms 306, 306–7
benztropine 90
β-blockers 543
bethanechol, sexual dysfunction 145, 146
bicarbonate, plasma 595
bilirubin, serum 595
binge eating disorder 529, 529
biochemical side-effects, psychotropic drugs 593–604, 594–9
bipolar disorder 153–96
antipsychotics 174–5, 182–4, 194
carbamazepine 168–73, 174–5, 194
children and adolescents 319, 321–6, 322–3, 324
HIV infection 565
lithium 159–68, 174–5, 194, 194–5
multiple sclerosis 524
physical monitoring 173–6, 174–5
pregnancy and postpartum 438–40, 440
prophylaxis 154, 168–9, 193–6
rapid-cycling 191–3, 192
valproate 153–9, 174–5, 194, 194–5
withdrawing anticonvulsants 429–30
see also depression, bipolar; mania
bleeding, SSRI-related 243, 252–5, 254
blood pressure (BP) after rapid tranquillisation 534, 535
antidepressants and 258–9
monitoring, schizophrenia 29
starting clozapine 64, 93
see also hypertension; hypotension
body dysmorphic disorder 296
borderline personality disorder (BPD) 545, 545–7
botulinum toxin clozapine-related hypersalivation 90
tardive dyskinesia 107
tics 347
bradykinesia 99
bradyphrenia 99
breast feeding 446–61, 447
antidepressants 448–52
antipsychotics 453–5
mood stabilisers 456–7
nicotine replacement therapy 401
opioid dependence 392–3
prescribing principles 446–7
sedatives 458
see also postpartum period
bromocriptine 125, 145
bulimia nervosa 527, 529, 529
buprenorphine 382–7
cautions 386
dose 383, 383–5, 385
dose reduction regimens 388, 389, 389
methadone vs 374, 375–6
NICE guidance 394
overdose 386
pregnancy and breast feeding 392, 393
transferring from methadone to 385–5, 384
withdrawal syndrome 375
bupropion (amlodipamone)
antipsychotic-induced weight gain 129
attention deficit hyperactivity disorder 332
bipolar depression 186
breast feeding 452
clozapine-related hypersalivation 90
discontinuation symptoms 275
dyskinesia 113–15
epigly 421
hyperprolactinaemia and 269
overdose 589
pregnancy 437
renal impairment 468
resistant depression 225
sexual dysfunction 145, 146, 266
smoking cessation 398, 399, 400–3
buspirone adults with learning disabilities 543
children and adolescents 328
renal impairment 473
resistant depression 228
sexual dysfunction 145, 146
y-butyrolactone (GBL) 408–10
butyrophenones breast feeding 453
overdose 589
cabergoline hyperprolactinaemia 125
resistant depression 229
caffeine 618–23
consumption in mental illness 621–2
content of drinks 619
interactions 620, 621
intoxication (caffeinism) 620, 620–1
psychotropic effects 619
calcium, plasma 596
calcium antagonists, tardive dyskinesia 107
cancer, psychostimulants for depression 241
cannabinoids, Tourette’s syndrome 347
cannabis 410, 412
drug interactions 415–16
capacity, mental assessment 644
learning disabilities 539
to refuse medication 629, 644
carbamazepine 168–73, 171
acute mania/hypomania 168
adults with learning disabilities 542
adverse effects 69–70
alcohol withdrawal 169, 369
attention deficit hyperactivity disorder 332
bipolar depression 168, 187
bipolar disorder 168–73, 174–5, 194
breast feeding 456
children and adolescents 354
costs 180
discontinuation 170
drug interactions 171–2, 422–3, 425
formulations 168
hepatic impairment 484
HIV infection 565
indications 168–9, 171
lithium interaction 165–6
mechanism of action 168
monitoring 170, 171
overdose 590
plasma levels 3, 169, 175
pregnancy 439, 440, 441
prescribing 171
renal impairment 464, 472
smoking and 616
street drug interactions 416
surgical patients 559
women of child-bearing age 170
cardiac arrhythmias see arrhythmias
cardioembolism, clozapine-induced 81–2
cardiovascular adverse effects
acetylcholinesterase inhibitors 497–8
antidepressants 257–64, 258–9
antipsychotics 115–23
clozapine 76, 81–2, 95
cardiovascular disease
prevention, dyslipidaemia 140
risk factors in schizophrenia 119–20, 134, 138
smoking cessation 399, 401–2
catatonia 113–15
malignant 113
management 113–14, 114
CATIE-AD study 510
child and adolescent depression 317
dementia 512, 513
hepatic impairment 479, 482
intravenous 286–9, 287
minimum effective dose 218
post-stroke depression 247
renal impairment 464, 468
resistant depression 222
swapping/stoping 270, 271–2
Clinical Institute Withdrawal Assessment for Alcohol, Revised Version (CIWA-Ar) 358, 359
clometiazole (chlormethiazole), renal impairment 473
clomipramine 207
adverse effects 249
anxiety disorders 296
breast feeding 448
clonidine
antipsychotic-induced akathisia 104
breast feeding 458
clonazepam equivalent dose 308
renal impairment 473
tardive dyskinesia 106
clomipramine
antipsychotic-induced akathisia 104
attention deficit hyperactivity disorder 332
autistic spectrum disorders 327, 328, 330
clomipramine-related hypersalivation 90
tics and Tourette’s syndrome 346
Clopizol see zuclopenthixol
clozapine 64–5
acute mania 179
adults with learning disabilities 541
adverse effects 75–88, 122, 151
common 76–7
community-based patients 95
management 75–8, 76–7
serious 80–4, 82
uncommon or unusual 78–80, 79
see also specific adverse effects
alternatives to 69–75, 70–2
augmentation 35, 52, 66–9, 67
bipolar disorder 183, 192
blood lipids and 139–40, 140
borderline personality disorder 545–6
breast feeding 454
caffeine interaction 621
chemotherapy and 88–9
children and adolescents 326, 334
community-based patients 92–5
adverse effects 95
initiation guidelines 92–5, 94
monitoring 92–5, 95
dementia 510
diabetes association 132–3, 135
dose 64–5
maximum licensed 17
starting regimen 64–5, 65
target 66
titration in community 93, 94
ECT seizure threshold and 237
epilepsy 422
hepatic impairment 480
HIV infection 564
hypnotonraemia 149
lithium combinations 84–8, 86
NICE guidance 12, 22, 23
overdose 589
Parkinson’s disease 520
plasma levels 3, 5–6, 66
pregnancy 434, 435
recommended use 26
renal impairment 465
sexual adverse effects 144
smoking and 616
surgical patients 561
switching to 34, 93
tardive dyskinesia and 106
cocaine 406, 412
drug interactions 415–16
Cockcroft and Gault equation 462
cognitive behavioural therapy (CBT) 520
child and adolescent bipolar disorder 194
child and adolescent anxiety disorders 327, 328, 330
child and adolescent depression 316, 318
depression in multiple sclerosis 523
insomnia 313
refractory schizophrenia 70
cognitive enhancing drugs see antidepressant drugs
cognitive impairment 572
multiple sclerosis 524–5
non-psychotherapeutic aspects 581
see also dementia
collitis, clozapine-induced 79
Committee on Safety of Medicines 201
Expert Working Group, on SSRIs 201
complementary therapies (CTs) 624–8, 625–7
dementia 514
compliance see adherence
compliance aids 25, 632
compliance therapy, schizophrenia 632
centration problems, non-psychotropics causing 581
Concerta XL
attention deficit hyperactivity disorder 335
see also methylphenidate
confusion, non-psychotropics causing 582
Confusion Assessment Method 547
consent, capacity to give 539
Confusion Assessment Method 547
confusion, non-psychotropics causing 581
delirium 547–54
delirium tremens (DTs) 356–7, 365
delirium 547–54
democlycine 149
dementia 490–518
administering medicines in foodstuffs 489
antidepressants 512–13
behavioural and psychological symptoms (BPSD) 509–18
benzodiazepines 512
driving regulations 634
Huntington’s disease 556
with Lewy bodies 505, 512
mood stabilisers/anticonvulsants 513
Parkinson’s disease 520–1
vascular 504–5
see also Alzheimer’s disease; antedementia drugs
depotent antipsychotics see long-acting injection (LAI) antipsychotics
depression 197–291
anticonvulsant-associated 420–3
benzodiazepines 302
bipolar 185–91
carbamazepine 168, 187
children and adolescents 324
lithium prophylaxis 160, 185–6
pregnancy 440
psychostimulants 240
treatment 185–8, 185–8
valproate 154
caffeine consumption 622
carbamazepine 168
children and adolescents 316–21
diabetes and 253–7, 256
driving regulations 637
elderly 220, 243–6, 244–5
psychostimulants 241
epilepsy 419–20
first episode 219
HIV infection 565
Huntington’s disease 556
information for patients 221
lithium 220
multiple sclerosis 522, 523
nicotine use 615
non-psychotropics causing 582
Parkinson’s disease 518, 519
postpartum 435–7
post-stroke 247, 247–8
pregnancy 435–7, 438
prescribing principles 199–200
psychostimulants 239–43, 240–1
psychotic 233–5, 234
recurrent 219, 219–20
resistant (refractory) 222–32, 223, 232
1st choice treatment 223–7, 224–5
2nd choice treatment 228, 228–9
children and adolescents 318–19
other treatments 229–30, 229–32
sexual dysfunction 246
St John’s wort 278–80, 279
treatment 197–201
algorithm 198
official guidance 200, 200–1, 201
see also antidepressants
desipramine, pregnancy 436
desmopressin 77, 148
dexamethasone, resistant depression 230
dexamfetamine
attention deficit hyperactivity disorder 332, 336
depression 240, 241
maintenance treatment 406–7
diabetes insipidus, nephrogenic, lithium-induced 162
diabetes mellitus
alcohol consumption 611
antipsychotic-associated 132–8, 151
depression and 253–7, 256
gestational 434
monitoring 134–5, 135
nicotine replacement therapy 402
schizophrenia association 132
diagnostic overshadowing 339
diamorphine see heroin
diazepam
alcohol withdrawal 362–3, 363, 369
antipsychotic-induced akathisia 104
benzodiazepine withdrawal 307, 308, 408
breast feeding 458
delirium 551
emulsion (Daizemuls) 303
654  Index

diazepam (cont.)
\(\gamma\)-butyrolactone withdrawal 409
Huntington's disease 555
rapid tranquillisation 533
children and adolescents 352
renal impairment 473
surgical patients 561
tardive dyskinesia 106
tolerance test 307
dihydropyrimidine 387
dimebon, Alzheimer's disease 503
discontinuation symptoms 274
antidepressants 270, 274–7, 275, 276
disinhibition, benzodiazepines and
304–6, 328
disintegrative disorder, childhood 337
disorientation, non-psychotropics
caus2ng 582
disulfiram 369, 371
diuretics, lithium interactions 164, 165
docosahexaenoic acid (DHA),
schizophrenia 96, 97
donepezil
adverse effects 498
Alzheimer's disease 490, 491–2, 499
behavioural and psychological
symptoms 511–12
delirium 551
dosing 491, 496
drug interactions 498–9, 500
ECT recovery and 237
efficacy 493, 495
Huntington's disease 556
mechanism of action 490
manganese with 502
multiple sclerosis 525
renal impairment 474
schizophrenia 58, 70
switching to/from 496
tardive dyskinesia 107
tolerability 497
vascular dementia 504
dosulepin (dothiepin) 208
adverse effects 249
breast feeding 448
depression prophylaxis 220
elderly 243
epilepsy 421
renal impairment 468
surgical patients 560
dothiepin see dosulepin
doxepin 208
adverse effects 249
rectal 289, 290
renal impairment 469
dreams, drug-induced 580
drink, covert administration of
medicines in 463–5
Driver and Vehicle Licensing Agency
(DVLA) 634, 636, 637–42
driving 634–43
drug-induced sedation 636
DVLA regulations 636, 637–42
effects of mental illness 634
effects of psychotropic drugs 634–6, 635
epilepsy and 423
GMC guidance 636
dosing 490
Drug Attitude Inventory 631
drug misuse/dependence 406–17,
411–13
benzodiazepines 407–8
driving regulations 642
\(\gamma\)-butyrolactone and
\(\gamma\)-hydroxybutyrate 408–10
NICE guidance 394–6
non-psychotropic medications
584
polysubstance abuse 407
psychotropic drug interactions
414–17, 415–16
stimulant drugs 406–7
urine testing 410, 411–13
see also opioid misuse/dependence;
'street drugs'
dual diagnosis 355, 410, 539
duloxetine 213
breast feeding 452
cardiac effects 259
diabetes and 256
ECT seizure threshold and 236
elderly 245
epilepsy 421
hepatic impairment 483
minimum effective dose 218
multiple sclerosis 523
overdose 588
relative adverse effects 249
renal impairment 469
sexual dysfunction and 265
smoking and 616
swapping/stopping 271–2
dyslipidaemia
antipsychotic-related 138–42
monitoring 27, 139–40, 140
pseudothymonatremia 148
treatment 31, 140
see also lipids, blood
dysthymia, antidepressant treatment
201–2
dystonia
acute, after rapid tranquillisation 531, 534
antipsychotic-induced 99–101
eating disorders 527–30
atypical 529
Erbstein's anomaly 439, 440
ECT see electroconvulsive therapy
Ecstasy, drug interactions 415–16
ECT see electroconvulsive therapy
efavirenz 569
eicosapentaenoic acid (EPA)
resistant depression 230
schizophrenia 96, 97
ejaculatory disorders 143
elderly 487–9
administering medicines in
foodstuffs 489
antipsychotics and
psychotropic-induced changes 117
ECT see electroconvulsive therapy (ECT)
cataton1a 113–14
child and adolescent depression 319
epilepsy 420
Huntington's disease 556
multiple sclerosis 523
Parkinson's disease 519, 520
pregnancy 437
psychotropic depression 233
psychotropics and 235–7, 235–9
refractory schizophrenia 70
resistant depression 224
electrolyte disturbances
alcohol-related 611
anorexia nervosa 527–8
emtricitabine 569
enfuvirtide 570
eosinophilia, cloza7ine-induced 79
eosinophil7s 600
epilepsy 419–30
anticonvulsant withdrawal 428–9, 429
antidepressant/antipsychotic use
419–20, 421–2
depression and psychosis 419–20
driving 423
learning disability 540
pregnancy 440–1, 441
see also anticonvulsants; seizures
EPS see extrapyramidal side-effects
Equasym see methylphenidate
Equasym XL
attention deficit hyperactivity disorder 335
see also methylphenidate
erectile dysfunction 143, 145
erythrocytes 600
erythrocyte sedimentation rate (ESR) 600
esetralopram 203
adverse effects 249
breast feeding 449
cardiac effects 258
child and adolescent depression 317
hepatic impairment 482
intravenous 287, 289
minimum effective dose 218
post-stroke depression 247
renal impairment 469
swapping/stopping 271–2
eszopiclone 312
ethanol see alcohol
ethosuximide, drug interactions 428
eutravirine 569
euphoria 57
fatigue 58
Fatal Toxicity Index (FTI) 262
extrapyramidal side-effects (EPS) 583
98–103, 99–101
antipsychotic polypharmacy 51
comparative table 151
first vs second-generation antipsychotics 39
switching antipsychotics 31
treatment 103–10
Fatality Toxicity Index (FTI) 262
fatigue
multiple sclerosis 525
non-psychotropics causing 583
extrapyramidal side-effects (EPS) 98–103, 99–101
antipsychotic polypharmacy 51
comparative table 151
first vs second-generation antipsychotics 39
switching antipsychotics 31
treatment 103–10
Fatal Toxicity Index (FTI) 262
fatigue
multiple sclerosis 525
non-psychotropics causing 583
ferritin, serum 597
fever, clozapine-induced 77, 93
financial incentives, medication adherence 632–3
first-generation antipsychotics (FGAs) adverse effects 40
bipolar disorder 178, 182–3
breast feeding 453
children and adolescents 326
delirium 549
dementia 509, 510–11
diabetes risk 132
dyslipidaemia and 139
long-acting injectable 41, 42
maximum licensed doses 16
minimum effective doses 15
negative symptoms 57
place in therapy 39–40
pregnancy 433, 435, 442
prophylaxis 61
recommended use 26
relative efficacy 11–12
fish oils see omega-3 fatty acids
fluid restriction, hyponatraemia 149, 251
flumazenil 303
guidelines for use 536
rapid tranquillisation and 533, 534
fluoxetine 204
adverse effects 249
antipsychotic-induced weight gain 129
anxiety disorders 296
bipolar depression 186, 187
breast feeding 449
cardiac effects 258
children and adolescents 354
anxiety 328, 329
autism spectrum disorders 338, 342, 343
depression 317, 318
diabetes and 256
eating disorders 528, 529
hepatic impairment 482
minimum effective dose 218
post-stroke depression 247
renal impairment 469
swapping/stopping 271–2
esetralopram 312
ethanol see alcohol
ethosuximide, drug interactions 428
etotravirine 569
inflammation 524
paracetamol 408–10
paracetamol-induced liver injury 408–10
fatigue 408–10
fluid restriction, hyponatraemia 408–10
fluid restriction, hyponatraemia 408–10
(potassium) 408–10
fluid restriction, hyponatraemia 408–10
parenteral nutrition 408–10
eating disorders 528, 529
fluid restriction, hyponatraemia 408–10
eating disorders 528, 529
flutamide, Tourette's syndrome 499
flutamide, Tourette's syndrome 499
food, covert administration of medicines in 489, 643–5
folic acid supplements
Alzheimer's disease 502
anticonvulsant-treated women 439, 440, 441
food, covert administration of medicines in 489, 643–5
full blood count (FBC), monitoring 27, 174
fusion inhibitors, HIV 570
 gabapentin
acute mania/hypomania 179
bipolar depression 187
drug interactions 427
tardive dyskinesia 107
galactorrhoea 123, 124, 143
galantamine
adverse effects 497–8
Alzheimer's disease 490, 491–2, 499
behavioural and psychological symptoms 511–12
dosing 491, 496
drug interactions 498–9, 500
efficacy 493–4, 495
mechanism of action 490
memantine with 502
renal impairment 475
tolerability 497
vascular dementia 504
γ-butyrolactone (GBL) 408–10
γ-glutamyl transferase (GHT) 499
γ-hydroxybutyrate (GHB) 408–10
gastrointestinal bleeds, SSRI-related 243, 252–3
gastro-oesophageal reflux disease (GORD), clozapine-induced 77
generalised anxiety disorder (GAD) 293
benzodiazepines 301–2
NICE guidance 297–8
pregabalin 297
SSRIs/SNRIs 292
General Medical Council (GMC), driving ability and 636
656 Index

Ginkgo biloba  
Alzheimer’s disease 502  
refractory schizophrenia 70  
schizophrenia 58, 67  
tardive dyskinesia 101  
ginseng, Alzheimer’s disease 503  
Glasgow Antipsychotic Side-effect Scale (GASS) 12  
glomerular filtration rate (GFR) 462, 463  
glucose, blood  
antidepressant effects 256  
bipolar disorder 174  
fasting plasma (FPG) 28, 95, 134, 135  
psychotropic drug effects 597  
random plasma (RPG) 95, 134, 135  
see also impaired glucose tolerance  
glycine, schizophrenia 58, 71  
glycopyrrolate 90  
granulocyte colony-stimulating factor (G-CSF) 88  
guanfacine 339, 346  
H₂ antagonists, antipsychotic-induced weight gain 129  
haematological side-effects, psychotropic drugs 593–604, 600–3  
haemoglobin glycated (HbA₁c) 134, 135, 597  
psychotropics affecting 600  
hallucinations  
alcohol withdrawal 369  
non-psychotropics causing 583, 585  
Parkinson’s disease 519  
haloperidol  
acute mania/hypomania 178  
adults with learning disabilities 541  
adverse effects 151  
alcohol withdrawal 369  
breast feeding 453  
clozapine augmentation 67  
costs 180  
delirium 549  
depot (haloperidol decanoate) 42, 43  
equivalent dose 14  
maximum licensed dose 17  
diabetes and 132  
epilepsy 421  
equivalent dose 14  
hepatic impairment 479, 480  
Huntington’s disease 554–6, 555  
maximum licensed dose 16  
minimum effective dose 15  
overdose 589  
pregnancy 433, 435, 442  
risk of prematurity 433–5  
rapid tranquillisation 531, 533  
children and adolescents 351  
refractory schizophrenia 72  
renin inhibition 464, 466  
sexual adverse effects 144  
smoking and 617  
speed and onset of action 37  
tics and Tourette’s syndrome 346  
heat stroke, clozapine-induced 79  
hepatic failure, clozapine-induced 79  
hepatic impairment 478–87  
antidepressants 482–3  
antipsychotics 480–1  
methadone dosing 379  
mood stabilisers 484  
nicotine replacement therapy 402  
psychening principles 478–9  
recommended drugs 479  
stimulants 483  
see also liver disease  
hepatitis B and C 414  
hepatic failure 478–87  
hepatic impairment 478–87  
hepatic side-effects, antipsychotic 478–87  
hepatic side-effects, psychotropic 478–87  
hepatic impairment 132  
hepatic impairment 148–50, 151  
antipsychotics not causing 123, 125  
antipsychotic switching 31  
treatment 124–5  
hypersalivation, clozapine-induced 76, 89–92, 90–1  
hypertension  
antipsychotics and 122–3  
clozapine-induced 76, 122  
Hypertension and 122–3  
hyperlipidaemia 139, 140  
hypnosis 624  
hypnotics 302, 310–11  
benzodiazepine 302, 312  
biochemical side-effects 594–9  
breast feeding 458  
driving and 635  
prescribing guidelines 311  
renal impairment 464, 473–4  
hypomana 176–82  
driving regulations 638  
non-psychotropics causing 583  
treatment 176–82, 177  
see also mania  
hypotension  
antipsychotics and 122–3  
clozapine-induced 76, 122  
Hypertension and 122–3  
hyperthyroidism, lithium-induced 162  
hypovolaemic shock 485  
Ibuprofen 237  
illicit drugs see ’street drugs’  
Iloperidone 18  
adverse effects 151  
minimum effective dose 15  
imipramine 208  
adverse effects 249  
child and adolescent depression 318–19  
hepatic impairment 479
pregnancy 436, 438
psychotic depression 233
rectal 289, 290
renal impairment 470
impaired glucose tolerance
antipsychotic-associated 132–8
switching antipsychotics 31
impulsiveness, autism spectrum disorders 339
inattention, autism spectrum disorders 339
indinavir 566–7
inositol 187
insomnia 310–14
cognitive behavioural therapy 313
drug treatment 310–12, 312
non-psychotropics causing 583
pregnancy 441–2
see also hypnotics
integrase strand transfer inhibitors 570
interferon-β therapy 522
international normalised ratio 633
interstitial nephritis, clozapine-induced 79
irapropium 90
irritability
autism spectrum disorders 339–40
non-psychotropics causing 583
isosorbide 210, 249
ketamine 187
ketonazole 230
lability, non-psychotropics causing 583
lactate dehydrogenase 597
lamivudine 570
lamotrigine
acute mania/hypomania 179
adults with learning disabilities 542
bipolar depression 186
bipolar disorder 192, 195
children and adolescents 319
breast feeding 456–7
clozapine augmentation 67
drug interactions 426
hepatic impairment 484
Huntington’s disease 555
overdose 590
plasma level monitoring 3
pregnancy 439, 440, 441
renal impairment 464, 472
resistant depression 228
schizophrenia 58, 71
unlicensed use 605
laughing and crying, pathological, in multiple sclerosis 524
learning disabilities (LD) 539–44
assessment of care environments 540
capacity and consent 539
driving regulations 639
medications used 541–3
physical co-morbidity 540
psychological interventions 540
sensitivity to side-effects 540
lethargy, non-psychotropics causing 581, 582
leucopenia, psychotropics causing 602
levetiracetam
acute mania/hypomania 179
bipolar disorder 192
drug interactions 427
Huntington’s disease 555
tardive dyskinesia 107
levomepromazine 16
levodopa
see also dyslipidaemia
Lewy body dementia 505, 512
libido (sexual desire) 142
reduced 143, 145, 264
lips, blood 598
senses 57
antipsychotic drug effects 138–42
monitoring 27, 139–40, 140, 174
see also dyslipidaemia
liproteins, plasma 597–8
lithium 159–68, 166
acute mania/hypomania 160, 178
adults with learning disabilities 543
adverse effects 161–2
augmentation of antidepressants 160–1
bipolar depression 160, 185–6
borderline personality disorder 546
breast feeding 457
caffeine interaction 621
children and adolescents 322, 341, 354
clozapine combinations 84–8, 86
costs 180
depression 220
discontinuation 163
driving and 633
drug interactions 164, 164–6
ECT seizure threshold and 236
epilepsy 421
formulations 160
hepatic impairment 479, 484
HIV infection 565
Huntington’s disease 556
hyponatraemia 149
indications 160–1, 166
mechanism of action 159–60
multiple sclerosis 524
on-treatment monitoring 163, 166
overdose 590
plasma level monitoring 3, 161, 175
pregnancy 438–9, 440
prescribing 166
pretreatment tests 162, 166
renal impairment 472
resistant depression 224
street drug interactions 416
suicide and 161
surgery and 562, 563
toxicity 162
women of child-bearing age 163
lithium carbonate 160
lithium citrate 160
liver disease
alcohol withdrawal 366–7
drug-induced 485
see also hepatic impairment
liver function tests (LFTs) 478, 485
bipolar disorder 174
buprenorphine and 386
clozapine-induced changes 79
monitoring 29, 95, 485
Liverpool University Neuroleptic Side-Effect Ratings Scale (LUNSERS) 12
lofepramine 209
adverse effects 249
cardiac effects 258, 261
elderly 244
hepatic impairment 482
minimum effective dose 218
overdose 588
renal impairment 470
lofexidine 90, 389
long-acting injection (LAI)
antipsychotics (depot antipsychotics) 12, 40–51
differences between 42
dose reduction 50, 30–1, 51
doses and frequencies 43
epilepsy 422
equivalent doses 14
first-episode schizophrenia 61
intramuscular anticholinergics and 42
maximum licensed doses 17
NICE guidance 23
non-adherent patients 632
prescribing advice 41
loop diuretics, lithium interaction 165
lopinavir 567
lorazepam
acute mania/hypomania 178
breast feeding 447
catatonia 113, 114
delirium 551
diazepam equivalent dose 308
hepatic impairment 479
Index

lorazepam (cont.)
rapid tranquillisation 532, 533
children and adolescents 352
renal impairment 464, 473
surgical patients 561
lorazepam 308, 312
low-density lipoprotein (LDL) 598
loxapine 151, 422
lurasidone 18
LY2140023 58
lymphocytes 601

maca root 266
mania
acute 176–82
antipsychotics 178, 182, 183
carbamazepine 168
drug costs 180
lithium 160, 178
pregnancy 440
treatment 176–82, 177, 179
valproate 154, 178
children and adolescents 321
driving regulations 638
multiple sclerosis 524
non-psychotropics causing 583
MAOIs see monoamine oxidase inhibitors
maraviroc 570
Maxepa see omega-3 fatty acids
MDA (3,4-
methylenedioxyamfetamine) 415–16
MDRD (Modification of Diet in Renal Disease) formula 462
mean cell haemoglobin 601
mean cell haemoglobin concentration 601
mean cell volume 601
mecamylamine 229
Medicines and Healthcare products
Regulatory Agency (MHRA)
methadone therapy 381
nicotine replacement therapy 400,
401–2
paediatric use of risperidone 341–2
SSRIs 201
Medikinet
attention deficit hyperactivity disorder 335
see also methylphenidate
melatonin
autism spectrum disorders 340
benzodiazepine withdrawal 309
child and adolescent insomnia 349–51
delirium 552
insomnia 311–12, 312
tardive dyskinesia 187
unlicensed use 605, 606
see also agomelatine
memantine
acute mania 179
adverse effects 498
Alzheimer’s disease 490, 491–2,
499
behavioural and psychological symptoms 512
catatonia 113
combination therapy 502
dementia with Lewy bodies 305
dosing 491, 496
drug interactions 501
efficacy 494, 495
Huntington’s disease 556
mechanism of action 490
refractory schizophrenia 70
renal impairment 475
switching to/from 496
tolerability 497
vascular dementia 504
mental illness
caffeine consumption 621–2
driving and 634, 637–42
learning disabilities 539
nicotine use 613
placebo effect 606–8
substance misuse 355, 410
see also specific conditions
metformin 129
methadone 377–82, 413
analgesia for patients on 380–1
buprenorphine vs 374, 375–6
cautions 379
dose 378–9
dose reduction regimens 388, 388
drug interactions 171, 415–16
NICE guidance 394
overdose 380, 591
pregnancy and breast feeding 392
QT prolongation 381–2, 382
surgery and 562
transferring to buprenorphine 383–5, 384
withdrawal symptoms 373, 375
methycellulose 129
3,4-methylenedioxyamfetamine (MDA) 415–16
methylphenidate
attention deficit hyperactivity disorder 332, 333, 334, 335
autism spectrum disorders 339
depression 239, 240, 241
driving and 635
hepatic impairment 483
psychotic depression 233
resistant depression 230
unlicensed use 605
metoclopramide, alcohol withdrawal 370
MHRA see Medicines and Healthcare products Regulatory Agency
mianserin 214
antipsycthc-induced akathisia 104
breast feeding 451
overdose 589
refractory schizophrenia 70
relative adverse effects 249
resistant depression 225
midazolam
rapid tranquillisation 531, 532, 533
children and adolescents 352
surgical patients 561
mifepristone 188, 233
mineral supplements, anorexia nervosa 527
minocycline, schizophrenia 58, 71, 73
mitotane 214
antipsychotic-induced akathisia 104
breast feeding 452
cardiac effects 257, 259
diabetes and 256
discontinuation symptoms 275
ECT seizure threshold and 236
elderly 245
epilepsy 421
hepatic impairment 483
hyperprolactinaemia and 269
intravenous 288, 289
minimum effective dose 218
multiple sclerosis 523
overdose 589
post-stroke depression 247
pregnancy 437
refractory schizophrenia 71
relative adverse effects 249
renal impairment 470
resistant depression 222, 225
sexual adverse effects 265
smoking and 617
swapping/stopping 270, 271–2
moclobemide 212
bipolar depression 187
breast feeding 451
cardiac effects 259
clozapine-related hypersalivation 90
epilepsy 421
hepatic impairment 482
minimum effective dose 218
multiple sclerosis 523
overdose 588
pregnancy 437
relative adverse effects 249
renal impairment 470
surgical patients 559
swapping/stopping 271–2
moclobemide
monoamine oxidase-A (MAO-A), reversible inhibitor 212, 249
see also moclobemide
monoamine oxidase inhibitors (MAOIs) 210–12
adverse effects 202, 249
breast feeding 451
caffeine interaction 621
heart effects 258
depression 202
diabetes and 256
discontinuation symptoms 275
drug interactions 285
ECT seizure threshold and 236
hepatic impairment 482
hyperprolactinaemia and 268
overdose 589
pregnancy 437
resistant depression 230
sexual adverse effects 265
surgery and 558, 559
swapping/stopping 271–2
monocytes 601
mood changes, non-psychotropics causing 583
mood disorders see affective disorders
mood stabilisers 194, 194–5, 195
acute mania/hypomania 176, 177
alcohol misuse 612
benzodiazepine withdrawal 109
biochemical side-effects 594–9
borderline personality disorder 546
breast feeding 447, 456–8
children and adolescents 322, 341
dementia 513
hepatic impairment 479, 484
HIV infection 565
multiple sclerosis 524
overdose 590
pregnancy 438–40, 440, 442
renal impairment 464, 472
withdrawing 429–30
see also anticonvulsants;
carbamazepine; lithium;
valproate
morphine 387
movement disorders, nicotine use 615
multiple sclerosis (MS) 522–6
multivitamins see vitamin supplements
music therapy 513–14
myocardial infarction (MI), antidepressant prescribing after 257, 258–9
myocarditis, clozapine-induced 76, 81–2, 82, 95
nabilone, Huntington’s disease 555
N-acetylcysteine, refractory schizophrenia 71
naltrexone
buprenorphine overdose 386
methadone overdose 380
opioid overdose 393
take-home 394
naloxone/nalbuphine (Suboxone) 374–6
naltrazepine
adults with learning disabilities 543
alcohol dependence 369, 370–1
NICE guidance 394
opioid dependence 390–1, 391
tardive dyskinesia 107
unlicensed use 605
National Institute for Health and Clinical Excellence (NICE)
adherence to medication 629, 630, 631
Alzheimer’s disease 499, 499
antipsychotics in pregnancy 434, 435
anxiety spectrum disorders 297–8
attention deficit hyperactivity disorder 333
benzodiazepines 292, 302
bipolar disorder 185, 194, 195
borderline personality disorder 545, 546
carbamazepine 168, 169, 170
child and adolescent depression 316, 317, 318
depression 200, 220
eating disorders 529
lipid-lowering guidance 140
lithium 160, 163
mood stabilisers in pregnancy 439, 440
obsessive compulsive disorder 297–8, 329–30, 330, 331
opioid dependence 374, 387–8, 394–6
rapid tranquillisation in pregnancy 442–3
schizophrenia 11, 22, 22–3
smoking cessation 398–9, 399, 400
valproate 154, 156
nausea, clozapine-induced 77
nefazodone, HIV infection 565
nelfinavir 567
nemifluride 230
neonates
antidepressant withdrawal effects 436, 437, 438
antipsychotic discontinuation symptoms 435
opioid withdrawal syndrome 392
see also breast feeding
nervousness, non-psychotropics causing 584
‘neuroleptic equivalents’ 13
neuroleptic malignant syndrome (NMS) 29, 110–13, 111
renal impairment and 464
neuroleptics see antipsychotics
neutropenia
benign ethnic 84–5
chemotherapy-associated 88
clozapine-induced 77, 79, 84–8
psychotropics causing 602
see also agranulocytosis
neutrophils 601–2
nevirapine 569
NICE see National Institute for Health and Clinical Excellence
nicotine 613–15
drug interactions 614, 616–17, 616–18
psychotropic effects 613
smoking cessation and 398–405
tourette’s syndrome 347
withdrawal symptoms 614–15
see also smoking, cigarette
nicotine replacement therapy (NRT) 398, 400
MHRA advice 400, 401–2
NICE guidance 399
types and doses 403
nimodipine, bipolar disorder 192
nitrazepam
diazepam equivalent dose 308
hypnotic use 312
nitrazepam equivalents 606
neuronal injury 437
non-psychotropics, psychiatric side-effects 579–86, 580–85

Index 659
non-steroidal anti-inflammatory drugs (NSAIDs) 164, 165
lithium interactions 164, 165
SSRI co-prescription 253
nortriptyline 209
adverse effects 249
child and adolescent depression 318–19
diabetes and 256
ECT and 237
Fatal Toxicity Index (FTI) 262
plasma level monitoring 3
post-stroke depression 247
pregnancy 436
renal impairment 470
resistant depression 230
transdermal patches 288, 290
nucleoside and nucleotide reverse transcriptase inhibitors 570
nucleoside reverse transcriptase inhibitors 568–9
obsessive compulsive disorder (OCD) 295
children and adolescents 328–32, 330
NICE guidance 297–8, 329–30, 330, 331
non-psychotropics causing 584
psychological therapies 297
SSRIs/SNRIs 295
ocular pigmentation, clonazepam-induced 79
oculogyric spasm (crisis) 99
oestrogens 528
anorexia nervosa 528
carbamazepine interaction 171
resistant depression 230
off-label prescribing 604–6, 605
paediatric practice 315
clonazepam acute intoxication with 'street drugs' 414
acute mania/hypomania 178, 183
adults with learning disabilities 541
adverse effects 151
anorexia nervosa 527, 528
bipolar depression 186
bipolar disorder 183, 192, 194, 195
blood lipids and 139–40, 140
breast feeding 447, 454–5
children and adolescents 354
bipolar disorder 323, 324
psychosis 326, 326
rapid tranquillisation 351
clonazepam augmentation 67
costs 20, 180
delirium 530
dementia 510, 511
diabetes association 133, 135
dose-response observations 33
epilepsy 421
hepatic impairment 480
high-dose 56
Huntington’s disease 555
long-acting injection (LAI) 18–19, 42
see also olanzapine pamoate (below)
maximum licensed dose 17
minimum effective dose 15
negative symptoms 57
overdose 589
pamoate 18–19, 43
cost 20
dose equivalence 18
plasma level monitoring 3, 6
pregnancy 433–4, 435
psychotic depression 233
rapid tranquillisation 531, 533
refractory schizophrenia 71, 72
relative efficacy 12
renal impairment 464, 466
resistant depression 224
sexual adverse effects 144
smoking and 617
speed and onset of action 37
surgical patients 561
switching to 26, 34–5
tardive dyskinesia and 106
Omacor see omega-3 fatty acids
omega-3 fatty acids (fish oils)
Alzheimer’s disease 503
bipolar depression 188
child and adolescent depression 319
clonazepam augmentation in pregnancy 437
refractory schizophrenia 71
resistant depression 230
schizophrenia 96, 96–8, 97
tardive dyskinesia 107
ondansetron
schizophrenia 58, 71, 73
tardive dyskinesia 107
opioid(s) analgesia, opioid-dependent patients 380
overdose 393, 393–4
withdrawal symptoms 373, 374
opioid misuse/dependence 372–98
buprenorphine substitution 382–7
buprenorphine vs methadone 374, 375–6
detoxification and reduction regimens 387–9, 388, 389, 395–6
evidence of 373
injectable maintenance opioids 387
methadone substitution 377–82
NICE guidelines 374, 387–8, 394–6
pain management 380–1, 386–7, 392
pregnancy and 376, 391–3
relapse prevention 389–91
substitute prescribing 373–87
treatment aims 372–3
oral glucose tolerance test (OGTT) 134, 135
orgasm 142
disorders 144, 145, 264
Orlistat 129
osteoporosis, anorexia nervosa 528
overactivity, autism spectrum disorders 339
overdose, psychotropic drug 587–93, 588–91
oxazepam
alcohol withdrawal 360, 366–7
diazepam equivalent dose 308
hepatic impairment 479
hypnotic use 312
renal impairment 474
oxcarbazepine
drug interactions 427
mania 178, 323
pregnancy 441
oxybutynin 91
oxytocin 338, 339
packed cell volume 602
paediatric autoimmune neuropsychiatric disorder associated with streptococcus (PANDAS) 347
paediatric patients see children and adolescents
pain management, opioid-dependent patients 380–1, 386–7, 392
paliperidone
adverse effects 151
cost 20
hepatic impairment 481
maximum licensed dose 17
palmitate long-acting injection 43, 47–50
cost 20
dose and administration 48
maximum licensed dose 17
risperidone equivalent doses 48
switching to 49
vs other depot antipsychotics 42, 45
plasma level monitoring 3
renal impairment 466
pancreatitis, clozapine-induced 79
Index

PANDAS 347
panic disorder 293
NICE guidance 297–8
non-psychotropics causing 584
SSRIs/SNRIs 296
Parkinson’s disease 518–22
dementia 520–1
depression 518, 519
nicotine use 615
psychosis 519, 520
paroxetine 205
adverse effects 202, 249
anxiety disorders 296
breast feeding 450
cardiac effects 258
child and adolescent anxiety 328
hepatic impairment 479, 482
minimum effective dose 218
pregnancy 436–7, 438
renal impairment 470
swapping/stopping 271–2
payments, medication adherence 632–3
Peony Glycyrrhiza Decoction 125
pergolide 347
pericardial effusions, clozapine-induced 79
pericyazine 16
perphenazine
adverse effects 151
equivalent dose 14
maximum licensed dose 16
personality change, non-psychotropics causing 584
personality disorders
borderline 545, 545–7
driving regulations 640
pervasive developmental disorders 337
pervasive developmental disorders—not otherwise specified (PDD–NOS) 337
P-glycoprotein 574
phenelzine 211
adverse effects 249
renal impairment 471
resistant depression 230
phenobarbital, interactions 427–8
phenothiazines
blood lipids and 139
breast feeding 453
diabetes risk 132, 135
ECT seizure threshold and 237
hepatic impairment 481
overdose 589
pregnancy 433
sexual adverse effects 144
phenytoin
acute mania 179
drug interactions 422, 426
plasma level monitoring 3
surgical patients 559
phosphate, plasma 598
phytomedical see herbal medicine
pimozide
adverse effects 151
clozapine augmentation 67
equivalent dose 14
maximum licensed dose 16
renal impairment 466
tics and Tourette’s syndrome 346
pindolol, resistant depression 228
pipotiazine (depot) 42, 43
adverse effects 151
equivalent dose 14
maximum licensed dose 17
renal impairment 466
pirenzepine 91, 606
placebo effect 606–8
plasma drug levels
meaningfulness 2
steady state 1
plasma level monitoring 1–10
criteria 1–2
interpreting results 2–7, 3–4
reasons for 2
sampling time 1–2
platelet counts 603
pneumonia 79, 130–1
polyunsaturated fatty acids (PUFAs)
see omega-3 fatty acids
postinjection syndrome, olanzapine 19
postpartum period
bipolar illness 438–40
depression 433–7
psychosis 432–4, 435
see also breast feeding
post-stroke depression 247, 247–8
psychostimulants 241
post-traumatic stress disorder (PTSD) 294
benzodiazepines 292
SSRIs/SNRIs 296
potassium, plasma 598
pramipexole
bipolar depression 187
Parkinson’s disease 519
resistant depression 230
pregabalin
anxiety disorders 297
benzodiazepine withdrawal 309
multiple sclerosis 524
pregnancy 430–46
alcohol use/withdrawal 371–2
anticonvulsants 441, 441, 442
antidepressants 436–7, 438, 442
antipsychotics 433–4, 435, 442, 442–3
benzodiazepine misuse 408
bipolar illness 438–40, 440
depression 435–7, 438
discussions with women 432
epilepsy 440–1, 441
mood stabilisers 438–40, 440, 442
opioid dependence 376, 391–3
prescribing principles 431–2
psychosis 432–4, 435
psychotropic drug choice 430–2, 442
rapid tranquillisation 442–3
sedatives 441–3, 442
smoking cessation 401
see also breast feeding, women of child-bearing age
pregnenolone 58
priapism 143, 144
promazine, adverse effects 151
promethazine
borderline personality disorder 546
breast feeding 458
insomnia 312, 312
pregnancy 442, 442
rapid tranquillisation 531, 533
renal impairment 474
street drug intoxication 414
propantheline 91
propentifylline 71
propranolol
anxiety disorders 297
antipsychotic-induced akathisia 101, 104
tardive dyskinesia 106
protease inhibitors, antiretroviral 566–8, 573
protein, serum 598
prothrombin time 603
pseudohypoparaemia 148
pseudo-parkinsonism, antipsychotic-induced 99–101
psychiatric disorders see mental illness
psychiatric side-effects
non-psychotropics 579–86,
psychological therapies
anxiety spectrum disorders 297
attention deficit hyperactivity disorder 332–3
child and adolescent depression 316–21
drug misuse 389–90, 395
eating disorders 527, 529, 529
learning disabilities 540
psychosis
anticonvulsant-associated 420
benzodiazepines 302–3
children and adolescents 326, 326–7
driving regulations 638, 639
epilepsy 419–20
first episode 60
HIV infection 564
Huntington’s disease 555–6
multiple sclerosis 524
non-psychotropics causing 584–5
Parkinson’s disease 519, 520
postpartum 452–4, 455
pregnant women 432–4, 435
sexual dysfunction 143
see also schizophrenia
psychostimulant drugs see stimulant drugs
psychotropics
biochemical side-effects 593–604, 594–9
breast feeding 446–61, 447
child and adolescent doses 354
cytochrome function and 574–9, 575–9
driving and 634–43, 635
ECT seizure threshold and 235–7, 235–8
haematological side-effects 593–604, 600–3
HIV infection 564, 564–73
overdose 587–93, 588–91
plasma level monitoring 1–10
pregnant women 430–2, 442
QTc prolongation 115–19, 117
smoking and 634–43, 635
special patient groups 419–586
street drug interactions 414–17, 415–16
surgery and 558–64, 559–62
PTSD see post-traumatic stress disorder
publication bias 607
pulmonary embolism
clozapine-induced hypersalivation 91
QTC prolongation 115–19
antidepressant-induced 258–9, 261
antipsychotic-induced 115–16
antipsychotic polypharmacy 51, 52
ECG monitoring 116, 116
management 120
metabolic inhibition 119
methadone and 381–2, 382
non-psychotropics inducing 119
psychotropic-related 115–19, 117
renal impairment and 463
risk factors 118, 118
switching antipsychotics 31
quetiapine
acute mania/hypomania 178
adults with learning disabilities 541
adverse effects 122, 131
anorexia nervosa 527, 528
augmentation 51
bipolar disorder 185, 185
bipolar disorder 183, 192, 194
children and adolescents 323, 324
blood lipids and 139
breast feeding 455
catatonia 114
children and adolescents 326
clozapine-related hypersalivation 91
costs 20, 180
delirium 550
dementia 510
diabetes association 133, 135
epilepsy 421
hepatic impairment 481
high-dose 54–6
Huntington’s disease 555, 556
maximum licensed dose 17
minimum effective dose 15
overdose 590
Parkinson’s disease 520
plasma level monitoring 3, 6–7
pregnancy 433–4
psychotic depression 233
refractory schizophrenia 72
relative efficacy 12
renal impairment 466
resistant depression 225
sexual adverse effects 144
speed and onset of action 37
switching to 34–5
tardive dyskinesia and 106
raltiregravir 570
ramelteon 312
rapid tranquillisation (RT) 531–2, 533
antipsychotics 531, 532, 533
benzodiazepines 302, 352, 533
children and adolescents 351–2, 351–3
physical monitoring 535
pregnancy 442–3
remedial measures 534
reboxetine 214
antipsychotic-induced weight gain 129
breast feeding 450
cardiac effects 259
diabetes and 256
elderly 245
epilepsy 421
hepatic impairment 483
hyperprolactinaemia and 269
minimum effective dose 218
overdose 588
post-stroke depression 247
pregnancy 437
publication bias 607
relative adverse effects 249
renal impairment 471
sexual adverse effects 265
swapping/stopping 271–2
red cell distribution width 603
reflux oesophagitis 79
renal function tests, bipolar disorder 174
renal impairment 462–78
antidementia drugs 474–5
antidepressants 468–71
antipsychotics 465–7
anxiolytics and hypnotics 473–4
classification 463
elderly 463
lithium-related 162, 472
methadone dosing 379
mood stabilisers 472
nicotine replacement therapy 402
prescribing principles 462–4
recommended drugs 464
renal replacement therapies 463
respiratory rate, after rapid
tranquillisation 534, 535
restlessness
non-psychotropics causing 584
see also akathisia
restricted repetitive behaviours and interests (RRBs) 338
reticulocyte count 603
Rett’s syndrome 337
riluzole
bipolar depression 180
Huntington’s disease 555
resistant depression 230
risperidone
acute mania/hypomania 178, 183
adults with learning disabilities 541
adverse effects 122, 151
Huntington’s disease 556
mechanism of action 490
memantine with 502
Parkinson’s disease 520–1
renal impairment 464, 475
tolerability 497
vascular dementia 504
RT see rapid tranquillisation
S-adenosyl-l-methionine 230
saffron 503–4
saquinavir 568
sarcosine 72
schizophrenia 11–152
acute exacerbation 25
adherence to medication 25, 42, 62,
629–30
caffeine consumption 621–2
cardiovascular risk factors 119–20,
134, 138
catatonia 113–14
children and adolescents 326,
326–7
complementary therapies 624
compliance therapy 632
diabetes association 132
drug association 132
first episode 24, 60
hyponatraemia 148
multi-episode 60–1
negative symptoms 57, 57–60, 58
NICE guidance 11, 22, 22–3
nicotine use 613–14
omega-3 fatty acids 96, 96–8, 97
refractory 64–95
relapse 25
sexual dysfunction 143
smoking cessation 404
treatment algorithms 24–5, 24–6
see also antipsychotics
scopolamine (hyoscine) 76, 90
second-generation antipsychotics
(SGAs) 39
adverse effects 39, 40
autism spectrum disorders 338,
339–40
bipolar disorder 178, 183, 194
children and adolescents 322,
323, 324
breast feeding 453–5
children and adolescents 326
costs 20, 20
delirium 549–51
dementia 509–11
diabetes risk 132–4
dyslipidaemia and 139
first-generation agents vs 39–40
inadequate response 34–6
long-acting injections 44–50
maximum licensed doses 17
minimum effective doses 15
negative symptoms 57
neuroleptic malignant syndrome 110
Parkinson’s disease 520
pregnancy 433–4, 435
prophylaxis 61
psychotic depression 233
rapid tranquillisation 531
relative efficacy 11–12
street drug interactions 415
treatment algorithms 24, 26
unlicensed use 605
sedation
alcohol-induced 611
antidepressant-induced 249
antipsychotic-induced 95, 151
clozapine-induced 76
driving ability and 636
non-psychotropics causing 585
switching antipsychotics 31
see also rapid tranquillisation
sedatives
borderline personality disorder 545, 546
breast feeding 447, 458
hepatic impairment 479
pregnancy 441–3, 442
renal impairment 464, 473–4
use of antipsychotics as 21
seizures
alcohol-related, driving regulations 641
alcohol withdrawal 356, 357, 369
antidepressant-induced 419–20
antipsychotic-induced 419–20
bupropion-related risk 402
clozapine-induced 77
see also epilepsy
selective serotonin reuptake inhibitors
(SSRIs) 203–6
adults with learning disabilities 542
adverse effects 202, 203–6, 249
antipsychotic-induced weight gain 129
anxiety disorders 292–7, 293–5
children and adolescents 328–9
autism spectrum disorders 338
bipolar depression 185, 186
bipolar disorder 194
bleeding and 252–5, 254
borderline personality disorder 546
breast feeding 449–50
caffeine interaction 621
cardiac effects 257
dementia 512–13
depression 202
Index

selective serotonin reuptake inhibitors (SSRIs) (cont.)
children and adolescents 317–18
minimum effective doses 218
official guidance 200, 201
diabetes and 256
discontinuation symptoms 275
drug interactions 216, 281–2, 284
eating disorders 529
ECT seizure threshold and 235
elderly 243, 245
epilepsy 421
hepatic impairment 482
HIV infection 565
Huntington’s disease 556
hyperprolactinaemia and 268
hynoponatraemia 251
lithium interactions 166
multiple sclerosis 523, 524
overdose 588
Parkinson’s disease 519
post-stroke depression 247
pregnancy 436, 437
resistant depression 225, 228, 230
schizophrenia negative symptoms 58
sexual adverse effects 145, 265
street drug interactions 416
surgeons patients 558, 560
swapping/stopping 271–2
selegiline 58, 146
sexual adverse effects 266
transdermal 288, 290
self-injurious behaviour (SIB) adults with learning disabilities 542–3
autism spectrum disorders 339–40
lithium therapy 161
semisodium valproate see valproate
Sequenced Treatment Alternatives to Relieve Depression (STAR-D) programme 217, 222, 223
D-serine, refractory schizophrenia 70
serotonin and noradrenaline reuptake inhibitors (SNRIs)
anxiety disorders 292–7, 293–5
diabetes and 256
discontinuation symptoms 275
hyperprolactinaemia and 269
multiple sclerosis 523
see also duloxetine; venlafaxine
serotonin syndrome 273
antidepressant interactions 284, 285
renal impairment and 464
St John’s wort 279
surgery-related risk 558, 560
serindole
adverse effects 151
breast feeding 455
cost 20
maximum licensed dose 17
minimum effective dose 15
refractory schizophrenia 72
sertraline 206
adverse effects 202, 249
anxiety disorders 296
breast feeding 447, 450
cardiac effects 258
child and adolescent depression 327, 328
child and adolescent schizophrenia 317
dementia 512, 513
hepatic impairment 482
minimum effective dose 218
multiple sclerosis 523
post-stroke depression 247
pregnancy 436, 437
psychotic depression 233
renal impairment 464, 471
swapping/stopping 271–2
sexual arousal 142
disorders 143, 144, 145, 264
sexual desire see libido
sexual dysfunction
antidepressants and 145, 264–8, 265
antipsychotic-related 40, 142–7, 144
depression and 264
hyperprolactinaemia and 123, 143, 145, 146
schizophrenia 143
switching antipsychotics 31
treatment 143–6, 145, 266
sexual response, human 142
Short Alcohol Withdrawal Scale (SAWS) 358,
360
sialorrhoea see hyperprolactinaemia
sildenafil
sialorrhoea
Short Alcohol Withdrawal Scale (SAWS) 358,
360
sleep
hygiene 310
smoking, cigarette 613–15
caffeine interaction 621
depression and anxiety 614
drug interactions 615, 616–17, 616–18
movement disorders 614
schizophrenia 613–14
see also nicotine
smoking cessation 398–405
bupropion 400–3
effects on other drugs 405
NICE guidance 398–9, 399, 400
psychiatric disorders 404
surgical patients 558
varenicline 403–4
see also nicotine replacement therapy
Snoezelen 513–14
social and communication impairment 339
social phobia 295, 296–7
sodium, plasma
monitoring 148, 250, 250, 251
psychotropics affecting 598
sodium oxybate, tardive dyskinesia 107
sodium valproate see valproate
SOHO trial 61
SSRIs see selective serotonin reuptake inhibitors
STAR-D programme 217, 222, 223
statins 140, 504
stavudine 569
stimulant drugs
attention deficit hyperactivity disorder 332, 335–6
depression 239–43, 240–1
hepatic impairment 483
misuse/dependence 406–7
resistant depression 230
St John’s wort (SJW) 278–80
child and adolescent depression 318
patient information 279
‘street drugs’
acute intoxication 414
interactions with prescribed psychotropics 414–17, 415–16
see also drug misuse/dependence
stroke
antipsychotic-treated elderly with 510–11
depression after 247, 247–8
SSRI-related risk 253–4
Suboxone 374–6
substance misuse 355–417
attention deficit hyperactivity disorder and 334
extrapyramidal symptom risk 102
NICE guidance 394–6
sudden cardiac death
antipsychotic-associated 28, 56, 115
clozapine-related 82
psychotropic-induced 119–20
see also QTc prolongation
suicide/suicidal ideation
antidepressants and 216
bipolar disorder 161, 185, 193
child and adolescent depression 317–18
epilepsy 419
Huntington’s disease 556
Index 665

lithium and 161
non-psychotropics causing 585
perioperative discontinuation of drugs 563
psychotropic overdose 587
sulpiride
adverse effects 122, 151
breast feeding 447, 453
clozapine augmentation 67
clozapine-related hypersalivation 91
epilepsy 421
equivalent dose 14
hepatic impairment 479, 481
Huntington’s disease 554
maximum licensed dose 16
minimum effective dose 15
refractory schizophrenia 71
renal impairment 467
sexual adverse effects 144
tics and Tourette’s syndrome 346
sumatriptan, intranasal 237
surgery, psychotropics and 558–64, 559–62
Symbyax 186
syndrome of inappropriate antidiuretic hormone
(SIADH) 148, 149, 250
tachycardia, clozapine-induced 76, 95
tamoxifen, acute mania 179
tantrums, autism spectrum disorders 339–40
tardive dyskinesia (TD) 99–101
first vs second-generation antipsychotics 40, 105–6
switching antipsychotics 31
treatment 105–10, 106, 107
TCAs see tricyclic antidepressants
temazepam
diazepam equivalent dose 308
hepatic impairment 479
hypnotic use 312
renal impairment 474
temperature, body
clozapine-induced increase 77, 93
rapid tranquillisation and 534, 535
tenofivir 569
terazosin 90
testosterone 58, 146, 230
tetrazenazine
Huntington’s disease 554
tardive dyskinesia 101, 106
Tourette’s syndrome 347
theophylline, carbamazepine interaction 171
therapeutic index, antipsychotics 39
thiamine
alcohol withdrawal 368, 369
post-ECT confusion 237
thiazide diuretics, lithium interaction 164, 165
thioridazine, adverse effects 144
thioxanthines
breast feeding 453
sexual adverse effects 144
thrombocytopenia, clozapine-induced 79
thromboembolism, clozapine-induced 81
thyroid function tests 174, 599
thyroxine
bipolar disorder 188, 192
carbamazepine interaction 171
psychotropics affecting 599
tagibine, interactions 428
tics 345–8
tiranavir 568
TMS see transcranial magnetic stimulation
tolvaptan 148
torpidamite, antipsychotic-induced weight gain 129
bipolar disorder 179, 192
clozapine augmentation 67
eating disorders 529
psychotropic drug interactions 428
refractory schizophrenia 72
torsade de points 115, 381–2
torticollis 99
Tourette’s syndrome 345–8
tranquilisation, rapid see rapid tranquillisation
tolbutamide
torsade de pointes 115, 381–2
trazodone
weekly dose 596

rectal 289, 290
relative adverse effects 249
renal impairment 471
sexual adverse effects 265, 266
swapping/stopping 271–2
Treatment of Adolescents with Depression Study 318
Treatment of Resistant Depression in Adolescence (TORDIA) studies 318
TREC studies 531, 532
tremor, valproate-induced 153
tricyclic antidepressants (TCAs)
adverse effects 202, 249
attention deficit hyperactivity disorder 332
breast feeding 448
cardiac effects 258, 261, 262
children and adolescents 318–19, 328
dementia 513
depression 202
elderly 244
epileptic impairment 482
HIV infection 565
Huntington’s disease 556
hypoprolactinaemia and 268
minimum effective doses 218
multiple sclerosis 523, 524
overdose 588
Parkinson’s disease 519
plasma level monitoring 4
pregnancy 436, 438
psychotic depression 233
resistant depression 230
sexual adverse effects 265
smoking and 617
street drug interactions 416
surgery and 558, 560
swapping/stopping 271–2
trifluoperazine
adverse effects 151
epilepsy 421
equivalent dose 14
maximum licensed dose 16
minimum effective dose 15
pregnancy 435, 442
renal impairment 467
triglycerides, plasma 139, 140, 599
trihexyphenidyl 90
triiodothyronine (T3) psyhotropics affecting 599
resistant depression 222, 224
Index

trimipramine 209
adverse effects 249
renal impairment 471
resistant depression 230
tryptophan 179, 229
UDP-glucuronosyl transferase (UGT) 574
unlicensed medicines 315
paediatric practice 315
see also off-label prescribing
urate/uric acid, plasma 599
urea, plasma 599
urea and electrolytes (U&Es), monitoring 27
valproate 157
acute mania/hypomania 154, 178
adults with learning disabilities 542
adverse effects 155–6
bipolar depression 154, 185
bipolar disorder 153–9, 174–5, 194, 194–5
breast feeding 447, 457
children and adolescents 322, 324, 341, 354
clozapine-induced seizures 77
costs 180
delirium 552
dementia 513
discontinuation 156
drug interactions 157, 426–7
formulations 153–4
hepatic impairment 484
Huntington’s disease 555
indications 154–5, 157
mechanism of action 153
monitoring 156, 157
overdose 590
plasma levels 4, 155, 175
pregnancy 439, 440, 441
refractory schizophrenia 72
renipal impairment 464, 472
street drug interactions 416
surgical patients 559
unlicensed use 605
women of childbearing age 156–7
valproic acid see valproate
vaptans 148
varenicline, smoking cessation 398, 399, 403–4
vascular dementia 504–5
vasculitis, clozapine-induced 79
venlafaxine 215
bipolar depression 186, 187
breast feeding 451
cardiac effects 259, 261
children and adolescents 328
ECT seizure threshold and 236
elderly 245
epilepsy 421
hepatic impairment 482
Huntington’s disease 556
minimum effective dose 218
multiple sclerosis 523
overdose 588
pregnancy 437
psychotic depression 233
relative adverse effects 249
renal impairment 471
resistant depression 222, 225, 228, 230
sexual adverse effects 265
surgical patients 560
swapping/stopping 271–2
vigabatrin, drug interactions 427
violent behaviour 531–8
driving regulations 640
recommended interventions 533
see also acutely disturbed behaviour
vitamin B 503
vitamin B complex (Pabrinex), alcohol withdrawal 367–8, 369
vitamin E 106, 502
vitamin K 439, 440, 441
vitamin supplements
Alzheimer’s disease 502
anorexia nervosa 527
water intoxication 148, 149
weight, monitoring
blood lipids and 139
bipolar disorder 175
breast feeding 455
children and adolescents 326
clozapine augmentation 67
delirium 551
diabetes and 134
dose-response observations 33
maximum licensed dose 17
minimum effective dose 15
overdose 590
rapid tranquilisation 531
children and adolescents 352
refractory schizophrenia 72
relative efficacy 12
renipal impairment 467
resistant depression 229
speed and onset of action 37
switching to 34–5, 128
zolpidem 311, 312
breast feeding 447, 458
overdose 591
renipal impairment 474
zonisamide 129, 188
zopiclone 311, 312
breast feeding 458
hepatic impairment 479
overdose 591
renipal impairment 464, 474
zopiclone, epilepsy 422
zuclopenthixol acetate (Acuphase), guidelines 537
acetylcholine
adverse effects 151
breast feeding 453
depot 42, 43
equivalent dose 14
maximum licensed dose 17
equivalent dose 14
maximum licensed dose 16
renipal impairment 467
smoking and 617